title: Reversible amiodarone-induced lung disease: HRCT findings.
abstract: The aim of this study was to describe thoracic high-resolution computed tomography (HRCT) findings of reversible amiodarone-induced lung disease (AILD). The thoracic HRCT of 20 symptomatic patients who were considered as having reversible AILD by the medical staff of our institution were retrospectively reviewed. The patient-selection criteria used were the development of new respiratory symptoms while receiving amiodarone, the exclusion of other respiratory and cardiac diseases, and the decrease of both respiratory symptoms and radiological abnormalities after cessation of amiodarone and corticotherapy. The CT data recorded were those usually sought infiltrative lung diseases. The radiological findings using chest film (n=20) and HRCT (n=4) follow-up was noted. All patients had ground-glass opacities, associated with consolidations (n=4), thin intralobular reticulations (n=5), or both (n=11), with a subpleural (n=18) or central (n=2) location. Eight patients had high-density areas and 13 had pleural thickening (n=13). Bronchial abnormalities included dilation (n=16) and wall thickening (n=19). After therapeutic management, the radiological follow-up showed complete (n=17) or incomplete (n=3) improvement. Ground-glass opacities associated with thin intralobular reticulations and/or subpleural consolidations and bronchial abnormalities are common HRCT findings in reversible AILD.
authors.affiliation: Department of Thoracic and Cardiovascular Radiology, Hopital Arnaud de Villneuve, 391, avenue du Doyen Giraud, 34295 Montpellier, France. h-vernhet@chu-montpellier.fr
authors.forename: H
authors.initials: H
authors.lastname: Vernhet
authors.forename: C
authors.initials: C
authors.lastname: Bousquet
authors.forename: G
authors.initials: G
authors.lastname: Durand
authors.forename: J
authors.initials: J
authors.lastname: Giron
authors.forename: J P
authors.initials: JP
authors.lastname: Senac
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011856:Radiographic Image Enhancement; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone